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ABSTRACT 67 
Objective: While bile acids are important for the digestion process, they also act as 68 
signaling molecules in many tissues, including the endocrine pancreas, which expresses 69 
specific bile acid receptors that regulate several cell functions. In this study, we 70 
investigated the effects of the conjugated bile acid TUDCA on glucose-stimulated 71 
insulin secretion (GSIS) from pancreatic β-cells.   72 
Methods: Pancreatic islets were isolated from 90-day-old male mice. Insulin secretion 73 
was measured by radioimmunoassay, protein phosphorylation by western blot, Ca2+ 74 
signals by fluorescence microscopy and ATP-dependent K+ (KATP) channels by 75 
electrophysiology.  76 
Results: TUDCA dose-dependently increased GSIS in fresh islets at stimulatory 77 
glucose concentrations but remained without effect at low glucose levels. This effect 78 
was not associated with changes in glucose metabolism, Ca2+ signals or KATP channel 79 
activity; however, it was lost in the presence of a cAMP competitor or a PKA inhibitor. 80 
Additionally, PKA and CREB phosphorylation were observed after 1-hour incubation 81 
with TUDCA. The potentiation of GSIS was blunted by the Gα stimulatory, G protein 82 
subunit-specific inhibitor NF449 and mimicked by the specific TGR5 agonist INT-777, 83 
pointing to the involvement of the bile acid G protein-coupled receptor TGR5.  84 
Conclusion: Our data indicates that TUDCA potentiates GSIS through the cAMP/PKA 85 
pathway. 86 
Keywords: β-cell, bile acids, insulin secretion, TUDCA 87 
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1. INTRODUCTION  88 
Bile acids are molecules derived from cholesterol and synthesized in 89 
hepatocytes. They facilitate the digestion and absorption of dietary lipids and fat-soluble 90 
vitamins and regulate cholesterol excretion and sterol homeostasis. Before secretion into 91 
the gallbladder and duodenum, bile acids undergo a conjugation process with glycine or 92 
taurine, which increases their solubility and decreases the toxicity of these compounds 93 
[1, 2, 3]. In addition to the digestive function of bile acids, the discovery of bile acid 94 
receptors in the last couple of years has emphasized their role as extracellular 95 
messengers, which produce both genomic and non-genomic effects through multiple 96 
signaling pathways [1, 2, 4, 5]. Many tissues, including the endocrine pancreas, express 97 
bile acid receptors [6, 7]. The most important of these receptors are the nuclear receptor 98 
Farnesoid X Receptor (FXR) and the G protein-coupled bile acid receptor TGR5 [1, 2, 99 
8].  100 
The activation of FXR can regulate several processes in pancreatic β-cells. In the 101 
insulin-producing cell line βTC6, the FXR agonist 6-ethyl-chenodeoxycholic acid (6E-102 
CDCA) increased the expression of insulin and the glucose-regulated transcription 103 
factor KLF11. It also induced AKT phosphorylation and GLUT-2 translocation to the 104 
plasma membrane, promoting glucose uptake [10]. The activation of FXR by the 105 
taurine-conjugated bile acid taurochenodeoxycholic acid (TCDC) increased glucose-106 
stimulated insulin secretion (GSIS) in isolated mouse islets. This effect was associated 107 
with the inhibition of ATP-dependent K+ (KATP) channels, changes in β-cell electrical 108 
activity, and increased Ca2+ influx [7]. The use of FXR ligands has also been explored 109 
in the treatment of glucose homeostasis disorders. The FXR ligand 6-ethyl-110 
chenodeoxycholic acid (6E-CDCA) decreased glucose, triglyceride and cholesterol 111 
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levels in db/db mice and Zucker fa/fa rats, improving glucose homeostasis in these 112 
diabetic models [8]. The FXR agonist obeticholic acid (OCA) ameliorated insulin 113 
sensitivity and the metabolic profile in patients with type-2 diabetes [10]. Activation of 114 
the G protein-coupled bile acid receptor TGR5 can also regulate pancreatic β-cell 115 
function. The TGR5 ligands oleanolic acid (OA) and INT-777 stimulated GSIS in the 116 
insulin-producing cells MIN-6 and human islets [6]. This effect depended on the 117 
activation of the Gα stimulatory TGR5 subunit, increasing adenylyl cyclase activity, 118 
cAMP levels, and cytosolic Ca2+ concentrations [6]. In rodents, synthetic TGR5 agonists 119 
diminished plasma glucose and insulin levels and protected against high-fat diet-120 
induced obesity [11]. TGR5 was also shown to be involved in glucose homeostasis 121 
through stimulation of the incretin glucagon-like peptide 1 (GLP-1) secretion [12, 13]. 122 
Although bile acids have recently been shown to be signaling messengers that 123 
are able to regulate some cellular processes in the endocrine pancreas, there is little 124 
information regarding their receptors, their molecular mechanisms and the actions 125 
involved. In this study, we analyzed the effects of the taurine-conjugated bile acid 126 
tauroursodeoxycholic acid (TUDCA) on the insulin secretory function of pancreatic β-127 
cells. TUDCA and ursodeoxycholic acid (UDCA) are used for the treatment of different 128 
liver diseases, such as primary biliary cirrhosis and cholesterol gallstones, but they also 129 
seem to have therapeutic potential in non-liver diseases, such as neurological, retinal, 130 
metabolic and myocardial disorders [14, 15]. These effects seem to be associated with 131 
their anti-apoptotic properties. Additionally, studies in experimental models of obesity 132 
have reported that TUDCA can act as a chemical chaperone that ameliorates insulin 133 
resistance by reducing endoplasmic reticulum stress and the unfolded protein response 134 
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[16]. Here, we show that TUDCA potentiates GSIS in pancreatic β-cells, likely through 135 




2. MATERIALS AND METHODS 138 
2.1 Reagents. TUDCA was purchased from Calbiochem (São Paulo, SP, BRA, cat. 139 
580549), and 125I was purchased from Genesis (São Paulo, SP, BRA). Western Blot 140 
reagents were purchased from Bio-Rad (Madrid, Spain), and antibodies were purchased 141 
from Cell Signaling (Barcelona, Spain). The remaining reagents were purchased from 142 
Sigma Chemical (St. Louis, MO, USA). 143 
2.2 Animals. All experiments involving animals were approved by the Animal Care 144 
Committee at UNICAMP (License Number: 2234-1) and Miguel Hernández University 145 
(ref. UMH.IB.IQM.01.13). Male 90-day-old C57Bl/6 mice were obtained from the 146 
breeding colony at UNICAMP and UMH and were maintained at 22 ± 1ºC on a 12-h 147 
light–dark cycle with free access to food and water. Mice were euthanized in a CO2 148 
chamber and decapitated for pancreatic islet isolation by collagenase digestion of the 149 
pancreas, as previous described [17].   150 
2.3 Insulin secretion. For static insulin secretion, pancreatic islets (4 islets per well) 151 
were incubated for 30 min with Krebs-Bicarbonate buffer (KBB; (in mM) 115 NaCl, 5 152 
KCl, 2.56 CaCl2, 1 MgCl2, 10 NaHCO3, 15 HEPES), supplemented with 5.6 mM 153 
glucose and 0.3 % BSA and equilibrated with a mixture of 95 % O2/5 % CO2 to 154 
regulate the pH at 7.4. After 30 min of preincubation time, the medium was removed 155 
and immediately replaced with fresh KBB medium containing different glucose and 156 
TUDCA concentrations, as well as the different reagents indicated in the experiments. 157 
After 1 h of incubation time, the medium was removed and stored at –20°C. For islet 158 
insulin content, groups of four islets were collected and transferred to tubes containing 1 159 
mL of deionized water, and the islet cells were homogenized using a sonicator 160 
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(Brinkmann Instruments, USA). Insulin levels were measured by a radioimmunoassay 161 
(RIA). Total islet protein was assayed using the Bradford dye method [18] with BSA as 162 
the standard curve. 163 
2.4 Cytoplasmic Ca2+ oscillations and NAD(P)H fluorescence. For cytoplasmic Ca2+ 164 
oscillations, fresh isolated islets were incubated with fura-2 acetoxymethyl ester (5 165 
µmol/L) for 1 hour at 37ºC in KBB buffer that contained 5.6 mM glucose, 0.3 % BSA 166 
and pH 7.4. Islets were then washed with the same medium and placed in a chamber 167 
that was thermostatically regulated at 37ºC on the stage of an inverted microscope 168 
(Nikon UK, Kingston, UK). Islets were perfused with albumin-free KBB that was 169 
continuously gassed with 95 % O2/5 % CO2 (pH 7.4). A ratio image was acquired every 170 
5 s with an ORCA-100 CCD camera (Hammamatsu Photonics, Iberica, Barcelona, 171 
Spain) in conjunction with a Lambda-10-CS dual filter wheel (Sutter Instrument 172 
Company, CA, USA), which was equipped with 340 and 380 nm, 10 nm bandpass 173 
filters and a range of neutral density filters (Omega opticals, Stanmore, UK). Ca2+-174 
dependent fluorescence in the recordings was displayed as the ratio F340/F380. The 175 
analysis was obtained using ImageMaster3 software (Photon Technology International, 176 
NJ, USA) [19]. Some data were represented as the area under the curve (AUC) of the 177 
last 10 min of the stimuli as a measure of the global Ca2+ entry [20]. NAD(P)H 178 
fluorescence was monitored using the same above-mentioned system, but fresh islets 179 
were excited with a 365-nm band pass filter, and the emission was filtered at 445 ± 25 180 
nm [21]. An image was acquired every 60 sec. 181 
2.5 Western blot analysis. Groups of 250 isolated islets were incubated in KBB 182 
medium containing 11.1 mM glucose and 50 µM TUDCA. Islets were then 183 
homogenized with 9 µL of Cell Lysis Buffer (Cell Signaling Technology, Danvers, 184 
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MA) and incubated for 0, 10, 20, 30 and 60 min in the conditions indicated in the figure 185 
legends. For SDS gel electrophoresis and western blot analysis, the samples were 186 
treated with a Laemmli sample buffer containing dithiothreitol. After heating to 95ºC 187 
for 5 min, the proteins were separated by electrophoresis in a 4–20% Mini Protean Gel 188 
(Bio-Rad, Hercules, CA, USA). Prestained SDS-PAGE standards were included for 189 
molecular mass estimation. Transfer to PVDF membranes was performed in a Trans 190 
Blot Turbo transfer for 7 min at 25 V with TRIS/glycine buffer (Bio-Rad, Hercules, CA, 191 
USA). After the membranes were blocked with 5% non-fat dry milk buffer (5% milk, 192 
10 mM TRIS, 150 mM NaCl and 0.02% Tween 20), they were incubated with a 193 
polyclonal antibody against phosphorylated (p)-CREBSer133 (1:1000; Cell Signaling 194 
#9198), CREB (1:1000; Cell signaling #4820), pPKA CThr197 (1:1000; Cell Signaling 195 
#5661), PKA C-α (1:1000; Cell signaling #4782) or GAPDH (1:1000; Cell Signaling 196 
#5174). GAPDH was used as a control for the experiment. The visualization of specific 197 
protein bands was performed by incubating the membranes with the appropriate 198 
secondary antibodies. Protein bands were revealed by using the Chemi Doc MP System 199 
(Bio-Rad, Hercules, CA, USA), which detects the chemiluminescence. The band 200 
intensities were quantified with Image Lab Lale 4.1 TM Software (Bio-Rad, Hercules, 201 
CA, USA). 202 
2.6 Patch-clamp recordings 203 
Islets were dispersed into single cells and cultured as previously described [22]. KATP 204 
channel activity was recorded using standard patch-clamp recording procedures. 205 
Currents were recorded by using an Axopatch 200B patch-clamp amplifier (Axon 206 
Instruments Inc., Union City, CA). Patch pipettes were pulled from borosilicate 207 
capillaries (Sutter Instrument Co., Novato, CA) using a flaming/brown micropipette 208 
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puller P-97 (Sutter Instrument Co.) with resistance between 3 and 5 MΩ when filled 209 
with pipette solutions, as specified below. The bath solution contained 5 mM KCl, 135 210 
mM NaCl, 2.5 mM CaCl2, 10 mM HEPES, and 1.1 mM MgCl2 (pH 7.4), and it 211 
supplemented with glucose as indicated. The pipette solution contained 140 mM KCl, 1 212 
mM MgCl2, 10 mM HEPES and 1 mM EGTA (pH 7.2). The pipette potential was held 213 
at 0 mV throughout the recording process. KATP channel activity was quantified by 214 
digitizing 60 sec sections of the current record filtered at 1 kHz and sampled at 10 kHz 215 
by a Digidata 1322A (Axon Instruments Inc., Orleans Drive Sunnyvale, CA, USA) and 216 
calculating the mean NPo during the sweep. Channel activity was defined as the product 217 
of N, the number of functional channels, and Po, the open state probability. Po was 218 
determined by dividing the total time channels spent in the open state by the total 219 
sample time. Values of NPo were normalized relative to the channel activity measured 220 
in control conditions before the application of different substances. Data sampling was 221 
initiated 1 min before (control) and 10–15 min after the application of the test 222 
substances. Experiments were carried out at room temperature (20–24ºC). These 223 
experiments were performed at 8 mM glucose, since at 11.1 mM glucose concentrations 224 
the majority of KATP channels are closed [20, 21, 22]. 225 
2.7 Statistical analysis. The results are presented as the mean ± SEM for the number of 226 
determinations (n) indicated. Statistical analysis was performed using Student’s t test or 227 
ANOVA with the appropriate post-test using Graph Pad Prism 5.0 software (La Jolla, 228 




3. RESULTS  231 
3.1 TUDCA stimulates insulin secretion in isolated islets. Mouse pancreatic islets 232 
incubated with TUDCA released more insulin than controls in a glucose-dependent 233 
manner. Although this bile acid had no effect at low concentrations, it increased 234 
glucose-induced insulin secretion (GSIS) at concentrations higher than 10 µM (Fig. 1). 235 
To address the mechanisms involved in the effects of TUDCA on GSIS, we performed 236 
the following experiments at a concentration of 50 µM. In agreement with the previous 237 
result, figure 2A shows that TUDCA increased insulin release from mouse islets 238 
incubated with 11 mM or higher glucose concentrations. The half-maximal effect 239 
(EC50) obtained from the dose-response curve (Fig. 2B) was calculated to be 13.78 ± 240 
1.03 mM glucose in islets incubated with TUDCA versus 15.47 ± 0.63 mM in controls. 241 
As indicated by the shift to the left of the dose-response curve and the magnitude of the 242 
secretory responses, TUDCA increased the β-cell responsiveness to glucose, leading to 243 
enhanced GSIS. No differences were observed in the total insulin content between 244 
TUDCA-treated and control cells (Fig. 2C), indicating that changes in insulin release 245 
were not mediated by TUDCA effects on insulin synthesis. 246 
3.2 TUDCA did not alter glucose-regulated NAD(P)H levels, electrical activity or 247 
Ca2+ signals in isolated islets. Several cell processes are involved in GSIS. When 248 
glucose enters β-cells, mitochondrial metabolism increases the cytosolic ATP/ADP 249 
ratio, leading to the closure of the KATP channels, which depolarizes the plasma 250 
membrane potential. This depolarization activates voltage-dependent Ca2+ channels, 251 
triggering a cytosolic Ca2+ rise that stimulates secretion. To study the involvement of 252 
these processes, we first monitored the glucose-induced changes through NAD(P)H 253 
levels. These levels increase as a result of glycolysis and Krebs cycle activation by 254 
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glucose, processes that are coupled to mitochondrial ATP production [23]. When mouse 255 
pancreatic islets were perfused in the presence or absence of the bile acid (Fig. 3A, B), 256 
no differences in glucose-induced NAD(P)H fluorescence levels were detected between 257 
the groups. We also explored the effect of TUDCA on glucose-regulated KATP channel 258 
activity because some bile acids, such as TCDC, have been shown to modulate this 259 
channel in pancreatic β-cells [7]. As shown in Figure 3C and D, TUDCA did not 260 
produce any effect on KATP channel activity with 8 mM glucose. These findings also 261 
indicate that TUDCA did not affect mitochondrial metabolism (as observed in Figure 262 
3A and B) because the KATP channel is highly sensitive to alterations in mitochondrial 263 
function and ATP levels [24]. Diazoxide is a potent KATP channel opener, which 264 
hyperpolarizes the plasma membrane, leading to reduced intracellular Ca2+ levels and 265 
insulin secretion. As expected, diazoxide decreased insulin secretion induced by 11 mM 266 
glucose (Supplementary Fig. 2A). Despite the inhibitory effect of the KATP channel 267 
opener, TUDCA was able to increase insulin secretion in the presence of diazoxide, 268 
suggesting that TUDCA effects are likely mediated by an alternative pathway that 269 
differs from the KATP channel route. Finally, we analyzed the effect of TUDCA on 270 
glucose-induced Ca2+ signals. TUDCA did not generate any effect when it was acutely 271 
applied to mouse islets in basal conditions (Fig. 4A) or after the generation of a Ca2+ 272 
increase with 11 mM glucose (Fig. 4B). No differences were observed in response to 273 
11.1, 16.7 or 22.2 mM glucose in pancreatic islets continuously perfused in the presence 274 
of 50 µM TUDCA compared to controls either (Fig. 4C–G and Supplementary. Fig. 1). 275 
Thus, it seems that the effect of TUDCA on GSIS is not mediated by KATP channel-276 
dependent mechanisms or Ca2+ signals. 277 
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3.3 The effects of TUDCA on GSIS likely depend on the G protein-coupled bile 278 
acid receptor TGR5. To further investigate the role of TUDCA on intracellular 279 
pathways, we also explored the types of bile acid receptors that were involved. Given 280 
that TUDCA has poor affinity for the nuclear receptor FXR [2, 3], we focused on 281 
TGR5, which is a G protein-coupled receptor that couples to the Gα stimulatory subunit, 282 
leading to the activation of adenylyl cyclase, the generation of cAMP and, subsequently, 283 
the activation of PKA [1]. We used NF449, a specific inhibitor of the Gα stimulatory G 284 
protein subunit. This inhibitor did not alter GSIS at 11.1 or 22.2 mM glucose levels 285 
(Fig. 5A and B), yet it abolished the stimulatory effects of TUDCA on GSIS at both 286 
glucose concentrations. Because there are no commercially available TGR5-selective 287 
antagonists [25], we tested the effect of INT-777 (6-alpha-ethyl-23(S)-methyl-cholic 288 
acid, 6-EMCA), a potent and selective TGR5 agonist. INT-777 totally mimicked the 289 
TUDCA action of 11 mM glucose, whereas it had no effect at basal glucose 290 
concentrations (Fig. 5B). These results indicate that a G protein-coupled receptor 291 
mediates TUDCA actions, likely via the TGR5 bile acid receptor. We also analyzed the 292 
effects of tauro β-muricholic acid (TβMCA), a natural FXR antagonist, to analyze 293 
whether this receptor participates in the actions of TUDCA. Incubation with TβMCA 294 
did not alter the effect of TUDCA on insulin secretion, indicating that this FXR was not 295 
involved (Supplementary Fig. 2B). 296 
3.4 TUDCA-stimulated insulin secretion is dependent on the cAMP/PKA pathway. 297 
To address whether the cAMP/PKA pathway could be modulated by TUDCA, we 298 
investigated the effect of the PKA inhibitor H89 and (Rp)-cAMP, a competitive 299 
inhibitor of PKA activation by cAMP, on GSIS. In both cases, the inhibition of the PKA 300 
pathway completely blunted the TUDCA actions on GSIS from mouse pancreatic islet 301 
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cells (Fig. 6A and B). In addition, to confirm the activation of this pathway, we 302 
analyzed the phosphorylation levels of PKA and its target protein CREB in a time-303 
dependent manner (Fig. 6C and D). TUDCA enhanced PKA and CREB 304 
phosphorylation after being incubated for 20 min. In addition, enhanced pPKA content 305 




4. DISCUSSION 308 
The present study shows that the taurine-conjugated bile acid TUDCA has a 309 
positive effect on glucose-induced insulin secretion from mouse isolated pancreatic 310 
islets, whereas it remains without effect at basal glucose levels. This behavior is similar 311 
to that of incretins such as GLP-1. Incretins exhibit an important therapeutic advantage 312 
for glycemic control in diabetes because they act on hyperglycemic conditions without 313 
favoring hypoglycemic episodes [26]. Thus, glucose-dependent TUDCA action on 314 
insulin secretion might be interesting from a therapeutic context. Currently, TUDCA 315 
and ursodeoxycholic acid (UDCA) are used for the treatment of several liver diseases 316 
[14,15]. In contrast to other bile acids, which are cytotoxic, TUDCA and UDCA exhibit 317 
protective properties against apoptosis [27]. Additionally, ongoing research is analyzing 318 
the therapeutic potential of TUDCA to alleviate apoptosis in non-liver diseases, such as 319 
neurological, retinal, metabolic and myocardial disorders [14, 15]. It has been reported 320 
in obese humans and mice that TUDCA ameliorates insulin resistance by reducing 321 
endoplasmic reticulum stress [6]. In addition to all of these beneficial properties, here, 322 
we show that TUDCA potentiates GSIS via bile acid signaling involving the 323 
cAMP/PKA pathway. This effect occurred over a short time period (less than 1 h) and 324 
was not mediated by genomic actions because insulin protein synthesis remained 325 
unchanged (Fig. 1 and 2). It remains to be explored whether in vitro TUDCA effects on 326 
GSIS are also important for in vivo conditions to acutely modulate plasma insulin levels 327 
and glucose homeostasis. It would also be interesting to analyze whether in vivo 328 
treatment with TUDCA alone or in combination with other therapeutic agents could 329 
ameliorate glycemic values in animal models of obesity and diabetes. 330 
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Although FXR and TGR5 are both expressed in mouse pancreatic islets [6, 7, 9], 331 
several findings support that the effects of TUDCA observed in this study were 332 
mediated, at least in part, by TGR5. In contrast to the nuclear FXR receptor, TGR5 is a 333 
plasma membrane receptor that is coupled to a G protein (Gα stimulatory), which 334 
activates adenylate cyclase, increasing cAMP levels. This results in PKA activation, 335 
inducing CREB phosphorylation [2, 3, 28]. Our results showed that the effects of 336 
TUDCA on GSIS were blocked when we inhibited both a G protein (Gα stimulatory) 337 
and PKA (Fig. 5 and 6). Additionally, TUDCA actions were mimicked by a TGR5 338 
selective agonist. We also showed that TUDCA increases PKA and CREB 339 
phosphorylation levels on the same temporal scale as the effects on GSIS. Remarkably, 340 
although TUDCA has been reported to activate TGR5 and to induce cAMP production 341 
[29, 30], this hydrophilic bile acid and UDCA are not FXR agonists [2, 30] because the 342 
latter receptor exhibits more affinity for hydrophobic bile acids. Taurine conjugation of 343 
UDCA may also increase its affinity for TGR5 [25, 31]. In contrast to the effects of the 344 
FXR agonist TCDC reported in mouse pancreatic islets [7], TUDCA actions on GSIS 345 
were independent of KATP channels and changes to cytosolic Ca2+ levels. These findings 346 
further support the idea that TUDCA affected secretion in the current study by 347 
mechanisms other than FXR activation.  348 
Short-term non-genomic effects on insulin secretion by some bile acids have 349 
been previously reported. The conjugated bile acid TCDC induced insulin release at 350 
high glucose concentrations via FXR activation in mouse β-cells [7]. In MIN-6 cells and 351 
human islets, the TGR5 agonists oleanolic (OA) and lithocholic acid (LCA) stimulated 352 
insulin secretion in both basal and stimulatory glucose conditions [6]. TUDCA 353 
enhanced insulin secretion in pig pancreatic islets at high glucose concentrations [32]. 354 
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In the latter study, the bile acid receptor mediating these TUDCA effects was not 355 
explored. Our findings are in agreement with these studies, showing that TUDCA 356 
stimulates high glucose-induced insulin secretion in the short-term. In βTC6 cells and 357 
human islets, the FXR ligand 6E-CDCA [9] was reported to enhance GSIS after an 18 h 358 
incubation. However, genomic actions were likely involved at these long periods 359 
because this FXR ligand also induced insulin expression.  360 
It has been shown that bile acids can regulate the activity of plasma membrane 361 
ion channels and cytosolic Ca2+ signals in different cell types [31]. In mouse isolated 362 
islets, the FXR agonist TCDC leads to the blockade of KATP channel currents, 363 
stimulating electrical activity and intracellular Ca2+ oscillations [7]. In MIN6 cells, 364 
mouse islets and human islets, different TGR5 agonists generate a rise in intracellular 365 
Ca2+ [6]. In this latter work, TGR5 activation led to phosphoinositide hydrolysis and 366 
Ca2+ release from intracellular stores. In our study, we did not observe any effects of 367 
TUDCA on KATP channel activity (Fig. 3), Ca2+ signals or intracellular Ca2+ release 368 
(Fig. 4), indicating that these pathways were not involved. It has been shown that the 369 
pharmacological activation of PKA can slightly increase glucose-induced intracellular 370 
Ca2+ concentrations [33]. Because we did not observe any effect on cytosolic Ca2+ 371 
levels, it seems that TUDCA may induce PKA activation to a low extent (at least 372 
compared with a pharmacological agonist) or that PKA-induced activation by TUDCA 373 
preferentially affects the secretory process. Indeed, changes in cAMP levels close to the 374 
plasma membrane and spatial compartmentalization of several components of the 375 
exocytotic process seem to play a major role in GSIS in pancreatic β-cells [34].  376 
TGR5 is a G protein-coupled receptor that leads to adenylate cyclase activation 377 
[31]. In the present study, incubation of isolated fresh islets with NF449, a Gαs subunit 378 
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inhibitor, prevented the effects of TUDCA on GSIS. Likewise, the inhibition of PKA 379 
activity with H89 or Rp-cAMPS resulted in the blockade of TUDCA actions. Finally, 380 
TUDCA led to PKA phosphorylation and activation of its target CREB in isolated 381 
mouse islets in the short-term. All of these findings indicate that the effects of TUDCA 382 
on GSIS are cAMP/PKA-dependent. The role of the cAMP/adenylate cyclase pathway 383 
in GSIS is well known. Elevation of cAMP concentrations potentiates glucose-384 
dependent insulin secretion through the activation of PKA [33, 35]. PKA 385 
phosphorylation affects the regulation of some proteins involved in exocytosis, thus 386 
stimulating insulin secretion in pancreatic β-cells [35, 36]. The present results are in 387 
agreement with previous studies on enteroendocrine cells showing that TGR5 activation 388 
is followed by Gαs release and activation of adenylate cyclase, leading to an increase in 389 
cAMP concentration and activation of PKA and CREB [3].  390 
In summary, this study shows an important effect of TUDCA in mouse 391 
pancreatic β-cells. This bile acid increases insulin secretion only at high glucose 392 
concentrations by a mechanism that is mediated by the cAMP/PKA/CREB pathway. 393 
Although our experiments indicate that the TGR5 receptor is likely involved in the 394 
effects of TUDCA, we cannot rule out the implication of the FXR receptor and other 395 
signaling pathways. 396 
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FIGURE LEGENDS 518 
Figure 1: Effects of different TUDCA concentrations on glucose-induced insulin 519 
secretion from mouse fresh islets. Groups of 4 islets were incubated for 1 h with 2.8, 520 
11.1, or 22.2 mM glucose (G) in the presence or absence of different TUDCA 521 
concentrations. Data are displayed as the mean ± SEM of 10-15 islet groups. In all of 522 
the experiments, glucose-induced secretion at 11.1 and 22.2 mM G was found to be 523 
significantly higher compared to that of the basal condition (2.8 mM G). * and #, 524 
significant differences (p<0.05) compared to the control conditions of 11.1 or 22.2 mM 525 
G, respectively.  526 
 527 
Figure 2: The effect of TUDCA is glucose-dependent. Effects of 50 µM TUDCA on 528 
glucose-induced insulin secretion (A, B) and total insulin content (C) from fresh mouse 529 
islets. Groups of 4 islets were incubated for 1 h at different glucose concentrations in 530 
the presence or absence of 50 µM TUDCA (A). EC50 values are also displayed in (B). 531 
Data are displayed as the mean ± SEM and were obtained from 10-15 groups of islets 532 
for each glucose concentration. *, significant differences (p<0.05) compared to control 533 
conditions.  534 
 535 
Figure 3: TUDCA effects are not mediated by metabolic changes. (A) 536 
Representative records of the changes in NAD(P)H fluorescence (%) in response to 0.5, 537 
5.6, 11.1 or 22.2 mM glucose from fresh mouse islets in the presence or absence of 538 
TUDCA. (B) Increment in NAD(P)H fluorescence (%) for each glucose concentration. 539 
Data are the mean ± SEM obtained from 4 to 6 independent experiments. (C, D) 540 
26 
 
Regulation of KATP channel activity in pancreatic β-cells of mice by 50 µM TUDCA. 541 
TUDCA did not produce any effect on the KATP channel activity at 8 mM glucose. (C) 542 
Records of KATP channel activity in the absence of glucose, 10 min after the application 543 
of 8 mM glucose, 10 min after the application of 8 mM glucose with 50 µM TUDCA, 544 
and 5 min after the application of 100 µM diazoxide. (D) Percentage of the KATP 545 
channel activity channel elicited by 0 mM glucose, 8 mM glucose, and 8 mM glucose 546 
and 50 µM TUDCA in single β-cells (n=6 cells). **, p<0.01 Student’s t-test comparing 547 
8 mM glucose and 8 mM glucose + 50 µM TUDCA with 0 mM glucose. 548 
 549 
Figure 4: TUDCA does not affect glucose-induced Ca2+ signals. (A, B) 550 
Representative Ca2+ recordings from isolated islets showing the lack of TUDCA effects 551 
when acutely applied at basal (2.8 mM) and stimulatory (11.1 mM) glucose 552 
concentrations. Three independent experiments were performed for each condition. (C, 553 
D) Representative Ca2+ recordings in response to 11.1 or 16.7 mM glucose from fresh 554 
mouse islets. The experiments were performed in a perfusion system in the continuous 555 
presence or absence of 50 µM TUDCA. The AUC (E, F, G) of Ca2+ is displayed as an 556 
indicator of the global Ca2+ entry for the different glucose concentrations. Data are 557 
shown as the mean ± SEM and were obtained from 4 to 6 independent experiments.  558 
Figure 5: TUDCA effects on GSIS are mediated by a G protein-coupled receptor. 559 
(A) TUDCA effects on insulin secretion induced by 11.1 and 22.2 mM glucose from 560 
mouse islets were abolished by the Gα stimulatory G protein subunit specific inhibitor 561 
NF449. (B) TUDCA effects on insulin secretion induced by 11.1 mM glucose from 562 
mouse islets were mimicked by the specific TGR5 agonist INT-777. Groups of 4 islets 563 
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were used in each measurement. Data are presented as the mean ± SEM and were 564 
obtained from 10 to 12 islets groups. *, significant differences (p<0.05) compared to 565 
control conditions.  566 
 567 
Figure 6: TUDCA actions on GSIS are mediated by the cAMP/PKA pathway. (A, 568 
B) Effects of TUDCA on GSIS from mouse islets after 1 h were blunted by the PKA 569 
inhibitor H89 (A) or by Rp-cAMP, a competitive inhibitor of PKA activation by cAMP 570 
(B). (C, D) TUDCA incubation for 1 h increases the phosphorylation of PKA (C) and 571 
CREB (D). Groups of 4 islets were used for insulin secretion measurements, and groups 572 
of 250 islets were used in the western blot experiments. Data are shown as the mean ± 573 
SEM and were obtained from 10 to 12 groups of islets. *, significant differences 574 
(p<0.05) compared to control conditions. 575 
 576 
Supplementary Figure 1: TUDCA does not affect glucose-induced Ca2+ signals. (A, 577 
B) Representative Ca2+ recordings from isolated islets showing the effect of TUDCA at 578 
basal (2.8 mM) and stimulatory (22.2 mM) glucose concentrations. Three independent 579 
experiments were performed in each condition. (C–H). The amplitude and Ca2+ 580 
oscillations from 22.2 and all of the glucose concentrations from the experiments shown 581 
in Figure 4. The experiments were performed in a perfusion system in the continuous 582 
presence or absence of 50 µM TUDCA. Data are shown as the mean ± SEM and were 583 
obtained from 4 to 6 independent experiments.  584 
Supplementary Figure 2: TUDCA effects on glucose-stimulated insulin secretion 585 
(GSIS) are not mediated by a KATP-dependent mechanism and FXR receptor. (A) 586 
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TUDCA effects on insulin secretion induced by 11.1 mM glucose from mouse islets 587 
were partially abolished by diazoxide. (B) TUDCA effects on insulin secretion induced 588 
by 11.1 mM glucose from mouse islets were not abolished by the natural FXR inhibitor 589 
TβMCA. Groups of 4 islets were used in each measurement. Data are displayed as the 590 
mean ± SEM and were obtained from 6 to 8 islets groups. * and #, significant 591 
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